A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
Solute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of tumor-associated ferroptosis. Accumulating evidence has demonstrated that xCT overexpression, resulting...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2022-10-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/1002101 |
| _version_ | 1811333688162516992 |
|---|---|
| author | Daniela Criscuolo Francesco Morra Angela Celetti |
| author_facet | Daniela Criscuolo Francesco Morra Angela Celetti |
| author_sort | Daniela Criscuolo |
| collection | DOAJ |
| description | Solute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of tumor-associated ferroptosis. Accumulating evidence has demonstrated that xCT overexpression, resulting from different oncogenic and tumor suppressor signaling, promotes tumor progression and multidrug resistance partially via suppressing ferroptosis. In addition, recent studies have highlighted the role of xCT in regulating the metabolic flexibility in cancer cells. In this review, the xCT activities in intracellular redox balance and in ferroptotic cell death have been summarized. Moreover, the role of xCT in promoting tumor development, drug resistance, and nutrient dependency in cancer cells has been explored. Finally, different therapeutic strategies, xCT-based, for anti-cancer treatments have been discussed. |
| first_indexed | 2024-04-13T16:56:40Z |
| format | Article |
| id | doaj.art-354e1901ca9442cb90134f2cc0554ff9 |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-04-13T16:56:40Z |
| publishDate | 2022-10-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-354e1901ca9442cb90134f2cc0554ff92022-12-22T02:38:47ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142022-10-013557058110.37349/etat.2022.00101A xCT role in tumour-associated ferroptosis shed light on novel therapeutic optionsDaniela Criscuolo0https://orcid.org/0000-0002-7581-0169Francesco Morra1https://orcid.org/0000-0003-4293-9238Angela Celetti2https://orcid.org/0000-0001-5166-3507Institute for the Experimental Endocrinology and Oncology, Research National Council, CNR, 80131 Naples, Italy; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, ItalyInstitute for the Experimental Endocrinology and Oncology, Research National Council, CNR, 80131 Naples, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalyInstitute for the Experimental Endocrinology and Oncology, Research National Council, CNR, 80131 Naples, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, ItalySolute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of tumor-associated ferroptosis. Accumulating evidence has demonstrated that xCT overexpression, resulting from different oncogenic and tumor suppressor signaling, promotes tumor progression and multidrug resistance partially via suppressing ferroptosis. In addition, recent studies have highlighted the role of xCT in regulating the metabolic flexibility in cancer cells. In this review, the xCT activities in intracellular redox balance and in ferroptotic cell death have been summarized. Moreover, the role of xCT in promoting tumor development, drug resistance, and nutrient dependency in cancer cells has been explored. Finally, different therapeutic strategies, xCT-based, for anti-cancer treatments have been discussed.https://www.explorationpub.com/Journals/etat/Article/1002101solute carrier family 7 member 11 (slc7a11)reactive oxygen species (ros) toleranceferroptosis-regulatorscoiled-coil domain containing 6 (ccdc6)cancer therapy |
| spellingShingle | Daniela Criscuolo Francesco Morra Angela Celetti A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options Exploration of Targeted Anti-tumor Therapy solute carrier family 7 member 11 (slc7a11) reactive oxygen species (ros) tolerance ferroptosis-regulators coiled-coil domain containing 6 (ccdc6) cancer therapy |
| title | A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options |
| title_full | A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options |
| title_fullStr | A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options |
| title_full_unstemmed | A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options |
| title_short | A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options |
| title_sort | xct role in tumour associated ferroptosis shed light on novel therapeutic options |
| topic | solute carrier family 7 member 11 (slc7a11) reactive oxygen species (ros) tolerance ferroptosis-regulators coiled-coil domain containing 6 (ccdc6) cancer therapy |
| url | https://www.explorationpub.com/Journals/etat/Article/1002101 |
| work_keys_str_mv | AT danielacriscuolo axctroleintumourassociatedferroptosisshedlightonnoveltherapeuticoptions AT francescomorra axctroleintumourassociatedferroptosisshedlightonnoveltherapeuticoptions AT angelaceletti axctroleintumourassociatedferroptosisshedlightonnoveltherapeuticoptions AT danielacriscuolo xctroleintumourassociatedferroptosisshedlightonnoveltherapeuticoptions AT francescomorra xctroleintumourassociatedferroptosisshedlightonnoveltherapeuticoptions AT angelaceletti xctroleintumourassociatedferroptosisshedlightonnoveltherapeuticoptions |